FDA issues blood centre/xenotransplant guidance:
This article was originally published in Clinica
Executive Summary
The US FDA has recommended that blood centres indefinitely defer collecting blood or plasma from recipients of a xenotransplant and their intimate contacts. The February 1 guidance document also contains recommendations on how to dispose of blood products manufactured from a donor who is discovered to have received a xenotransplant after the fact or to have been an intimate contact of a recipient of a xenotransplant. This is the second draft of the guidance document, altered to incorporate revisions based on public comments to the first draft published in the Federal Register on December 30 1999.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.